| Bioactivity | SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity[1]. |
| CAS | 205645-02-9 |
| Formula | C24H27N4NaO7S |
| Molar Mass | 538.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. SPD-502: A Water-Soluble and In Vivo Long-Lasting Ampa Antagonist with Neuroprotective Activity |
SPD-502 sodium
CAS: 205645-02-9 F: C24H27N4NaO7S W: 538.55
SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.